iCAD/$ICAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iCAD
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Ticker
$ICAD
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
66
ISIN
US44934S2068
Website
iCAD Metrics
BasicAdvanced
$105M
-
-$0.20
1.36
-
Price and volume
Market cap
$105M
Beta
1.36
52-week high
$4.02
52-week low
$1.18
Average daily volume
297K
Financial strength
Current ratio
3.656
Quick ratio
3.466
Long term debt to equity
0.237
Total debt to equity
0.997
Interest coverage (TTM)
-481.00%
Profitability
EBITDA (TTM)
-5.081
Gross margin (TTM)
87.90%
Net profit margin (TTM)
-26.77%
Operating margin (TTM)
-29.56%
Effective tax rate (TTM)
-1.83%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-9.03%
Return on equity (TTM)
-16.53%
Valuation
Price to revenue (TTM)
5.186
Price to book
3.38
Price to tangible book (TTM)
4.66
Price to free cash flow (TTM)
-30.924
Free cash flow yield (TTM)
-3.23%
Free cash flow per share (TTM)
-12.39%
Growth
Revenue change (TTM)
8.86%
Earnings per share change (TTM)
123.35%
3-year revenue growth (CAGR)
-15.63%
10-year revenue growth (CAGR)
-8.75%
3-year earnings per share growth (CAGR)
-27.75%
10-year earnings per share growth (CAGR)
1.12%
What the Analysts think about iCAD
Analyst ratings (Buy, Hold, Sell) for iCAD stock.
iCAD Financial Performance
Revenues and expenses
iCAD Earnings Performance
Company profitability
iCAD News
AllArticlesVideos
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
Business Wire·4 weeks ago
iCAD Reports Financial Results for First Quarter Ended March 31, 2025
GlobeNewsWire·2 months ago
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iCAD stock?
iCAD (ICAD) has a market cap of $105M as of June 30, 2025.
What is the P/E ratio for iCAD stock?
The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of June 30, 2025.
Does iCAD stock pay dividends?
No, iCAD (ICAD) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next iCAD dividend payment date?
iCAD (ICAD) stock does not pay dividends to its shareholders.
What is the beta indicator for iCAD?
iCAD (ICAD) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.